Table 2.

Clinical features of the study eye

	Number (%), N=32
Study eye characteristics
Laterality
Right	15 (47)*
Left	17 (53)
IIRC Group at Diagnosis
Group D	5 (16)
Group E	27 (84)
Enucleation
Primary	28 (88)
Secondary	4 (12)
Buphthalmic	7 (22)
Orbital optic nerve enhancement on MRI (extraocular disease at diagnosis)	8 (25)
Clinical TNM stage (all N0M0)
cT2	17 (53)
cT2a	3
cT2b	14
cT3	6 (19)
cT3b	2
cT3c	4
cT4	9 (28)
Primary treatment
Enucleation	28 (88)
Systemic Chemotherapy	14 (44)
Intra-arterial chemotherapy	6 (19)

^*Patient #17 had enucleation of the right eye without sufficient viable tumor for genetic sequencing, due to pre-enucleation chemotherapy with disease the chiasm on MRI at presentation. Patient #30 presented with orbital extension of the right eye, and biopsy of the orbital mass was performed at an outside institution. Pre-enucleation chemoreduction was given, with plan for enucleation after chemotherapy is completed.